No Data
No Data
Dynavax Technologies (NASDAQ:DVAX) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet
H.C. Wainwright Maintains Dynavax Technologies(DVAX.US) With Buy Rating, Maintains Target Price $29
H.C. Wainwright analyst Edward White maintains $Dynavax Technologies(DVAX.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 28
Dynavax Reports First Participant Dosed in Shingles Vaccine Trial
Dynavax Technologies (DVAX) said late Thursday the first participant has been dosed in its phase 1/2 study of its vaccine candidate Z-1018 to prevent shingles, a disease caused by the varicella-zoster
Express News | Dynavax Initiates Phase 1/2 Study Of Novel Shingles Vaccine Program Evaluating Safety, Tolerability And Immunogenicity Of Z-1018
Express News | Dynavax Technologies Corp: Anticipates Reporting Top Line Immunogenicity and Safety Data in Second Half of 2025
Express News | Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program